ARCHIVES

Gregory Reaman Named Associate Director of FDA Office of Oncology Drug Products

This article is from The Cancer Letter archive.

Vol. 37 No. 22 | June 3, 2011

Download PDF Visit The Full Archive

Related Articles

Comprehensive Centers Could Lose That Designation By Not Producing

May 30, 1975

Sorafenib Targets AML Driven By Mutant FLT3 Gene

February 29, 2008

Letter to the Editors: Scientists, Media Shouldn’t Overstate “Breakthroughs”

May 29, 1998

With Flashing Lights, Heckling, and Folk Song, Avastin Sets New Tone for FDA Debates

July 1, 2011

Prostate Cancer Prevention Trial Begins At 222 U.S. Sites

October 22, 1993

Proflavine Bioassay Ineffective, NCI Says

July 15, 1977